NCT00005903 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Litvan I
The clinical and pathologic hallmarks of progressive supranuclear palsy. Curr Opin Neurol. 1997 Aug;10(4):346-50. Review.
Pahwa R
Progressive supranuclear palsy. Med Clin North Am. 1999 Mar;83(2):369-79, v-vi. Review.
Santacruz P, Uttl B, Litvan I, Grafman J
Progressive supranuclear palsy: a survey of the disease course. Neurology. 1998 Jun;50(6):1637-47.

Dose-Escalation Trial of Continuously Infused Recombinant-Methionyl Human Glial Cell Line-Derived Neurotrophic Factor for the Treatment of PSP

Clinical trial NCT00005903 - References